PMID: 9441157Jan 24, 1998Paper

Conservative therapeutic approaches in terminal coronary heart disease. Chronic intermittent urokinase therapy

Herz
M LeschkeB E Strauer

Abstract

Despite progress in the invasive revascularization procedures and even though conventional antianginal treatment has improved the quality of life in patients with symptomatic coronary artery disease considerably, an increasing number of patients suffers from end-stage coronary artery disease and refractory angina pectoris. For these refractory patients long-term intermittent urokinase therapy was developed as an antithrombotic intervention, which is based on its capacity to enhance thrombolysis and blood rheology, and may possibly lead to plaque regression. The coronary syndrome of refractory angina pectoris is characterized by a mismatch of severe coronary insufficiency and a relatively large amount of viable myocardium as indicated by an only moderately impaired left ventricular function. Prior to initiation of long-term intermittent urokinase therapy all potential measures to improve myocardial perfusion have to be considered in each patient. These supportive measures include rigorous reduction of LDL-cholesterol, which has proven antiischemic properties due to an improved endothelial function of epicardial conductance vessels possibly resulting in an antianginal effect. Apart from the proven antiischemic properties of long-...Continue Reading

References

Jan 23, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Jan 30, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Jan 17, 1992·Deutsche medizinische Wochenschrift·M LeschkeB E Strauer
Feb 1, 1990·Mayo Clinic Proceedings·C Shub
Dec 1, 1990·Atherosclerosis·P BroadhurstE B Raftery
Mar 1, 1990·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·E B SmithC Stirk
Nov 1, 1989·Stroke; a Journal of Cerebral Circulation·A SchneidauT W Meade
Jan 1, 1988·British Heart Journal·C MannheimerC Wilhelmsson
Jul 29, 1988·Deutsche medizinische Wochenschrift·M LeschkeB E Strauer
Sep 18, 1985·The American Journal of Cardiology·A MaseriJ C Kaski
Apr 1, 1984·Journal of the American College of Cardiology·M TolinsG L Pierpont
Nov 6, 1981·Deutsche medizinische Wochenschrift·H Schmid-Schönbein
Aug 1, 1995·Circulation·E FalkV Fuster
Feb 23, 1995·The New England Journal of Medicine·T J AndersonP Ganz
Mar 3, 1995·Deutsche medizinische Wochenschrift·F C SchoebelB E Strauer
Mar 1, 1997·Zeitschrift für Kardiologie·H NägeleH M Stubbe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.